NO20015428L - Anvendelse av selektive antagonister for den <alfa>1b- adrenerge reseptor for forbedring av seksuell dysfunksjon - Google Patents

Anvendelse av selektive antagonister for den <alfa>1b- adrenerge reseptor for forbedring av seksuell dysfunksjon

Info

Publication number
NO20015428L
NO20015428L NO20015428A NO20015428A NO20015428L NO 20015428 L NO20015428 L NO 20015428L NO 20015428 A NO20015428 A NO 20015428A NO 20015428 A NO20015428 A NO 20015428A NO 20015428 L NO20015428 L NO 20015428L
Authority
NO
Norway
Prior art keywords
adrenergic receptor
sexual dysfunction
selective antagonists
alfa
improve sexual
Prior art date
Application number
NO20015428A
Other languages
English (en)
Other versions
NO321841B1 (no
NO20015428D0 (no
Inventor
Amedeo Leonardi
Gianni Motta
Rodolfo Testa
Giorgio Sironi
Original Assignee
Recordati Chem Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Chem Pharm filed Critical Recordati Chem Pharm
Publication of NO20015428L publication Critical patent/NO20015428L/no
Publication of NO20015428D0 publication Critical patent/NO20015428D0/no
Publication of NO321841B1 publication Critical patent/NO321841B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9433—(Nor)adrenaline
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
NO20015428A 1999-05-07 2001-11-06 Anvendelse av selektive antagonister for den a1b-adrenerge reseptor for forbedring av seksuell dysfunksjon NO321841B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI000995A IT1312310B1 (it) 1999-05-07 1999-05-07 Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
PCT/EP2000/004308 WO2000067735A2 (en) 1999-05-07 2000-05-08 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION

Publications (3)

Publication Number Publication Date
NO20015428L true NO20015428L (no) 2001-11-06
NO20015428D0 NO20015428D0 (no) 2001-11-06
NO321841B1 NO321841B1 (no) 2006-07-10

Family

ID=11382912

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015428A NO321841B1 (no) 1999-05-07 2001-11-06 Anvendelse av selektive antagonister for den a1b-adrenerge reseptor for forbedring av seksuell dysfunksjon

Country Status (25)

Country Link
US (2) US6303606B1 (no)
EP (1) EP1177190B1 (no)
JP (1) JP2002544158A (no)
KR (1) KR100696755B1 (no)
CN (1) CN1150187C (no)
AT (1) ATE308538T1 (no)
AU (1) AU765487B2 (no)
BR (1) BR0010348A (no)
CA (1) CA2366201A1 (no)
DE (1) DE60023686T2 (no)
DK (1) DK1177190T3 (no)
ES (1) ES2250130T3 (no)
HK (1) HK1039900B (no)
HU (1) HUP0201184A3 (no)
IL (1) IL146003A0 (no)
IT (1) IT1312310B1 (no)
MX (1) MXPA01011261A (no)
NO (1) NO321841B1 (no)
NZ (1) NZ515240A (no)
PL (1) PL196708B1 (no)
RU (1) RU2239633C2 (no)
SI (1) SI1177190T1 (no)
TW (1) TWI224503B (no)
WO (1) WO2000067735A2 (no)
ZA (1) ZA200110042B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
WO2005025570A1 (en) * 2003-09-15 2005-03-24 Diamedica Inc. Use of antagonists of hepatic sympathetic nerve activity
US20050124625A1 (en) * 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005112889A2 (en) * 2004-05-20 2005-12-01 Recordati Ireland Limited Transmucosal delivery formulations
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
AU2005296719B2 (en) * 2004-10-18 2011-02-03 Polymun Scientific Immunbiologische Forschung Gmbh Liposomal composition comprising an active ingredient for relaxing smooth muscle production and therapeutically use of said composition
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
EP2054041A2 (en) 2006-08-14 2009-05-06 Boehringer Ingelheim International GmbH Formulations of flibanserin and method for manufacturing the same
IL197129A (en) 2006-08-25 2014-08-31 Boehringer Ingelheim Int Controlled release system and method for production
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
CN101592613B (zh) * 2009-07-06 2011-12-21 广东省药品检验所 一种中成药、保健食品和食品中添加pde5型抑制剂的检测方法
DK2616460T3 (en) * 2010-09-13 2016-01-18 Otsuka Pharma Co Ltd HETEROCYCLIC COMPOUNDS FOR TREATMENT OR PREVENTION OF DISEASES CAUSED BY decreased neurotransmission of serotonin, norepinephrine or dopamine
JP6415982B2 (ja) * 2012-03-12 2018-10-31 大塚製薬株式会社 複素環化合物
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en) 2012-06-04 2017-02-22 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
RU2018145364A (ru) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
TW213903B (no) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5474994A (en) 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
IT1254469B (it) 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
US5773457A (en) 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
DE69423533T2 (de) 1993-02-10 2000-08-24 B.M.R.A. Corp. B.V., Rotterdam Zubereitungen zur Behandlung von Impotenz, die ein Alpha-1 inhibitor und ein Alpha-2 inhibitor enthalten
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
NZ305560A (en) 1995-03-14 1998-11-25 Vivus Inc Method for preventing erectile dysfunction by administering vasoactive agent, particularly a prostaglandin, kit therefor
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
JPH11512710A (ja) 1995-09-29 1999-11-02 メルク エンド カンパニー インコーポレーテッド アルファ１ｂアドレナリンレセプターアンタゴニスト
US5700364A (en) 1995-10-30 1997-12-23 Merck & Co., Inc. Electrochemical oxidation
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
EP1027054A4 (en) * 1997-10-28 2002-11-04 Vivus Inc LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
PL196708B1 (pl) 2008-01-31
KR20020002494A (ko) 2002-01-09
ES2250130T3 (es) 2006-04-16
IT1312310B1 (it) 2002-04-15
MXPA01011261A (es) 2002-08-12
ZA200110042B (en) 2002-07-02
NO321841B1 (no) 2006-07-10
DE60023686D1 (de) 2005-12-08
ITMI990995A1 (it) 2000-11-07
TWI224503B (en) 2004-12-01
HUP0201184A3 (en) 2003-05-28
ATE308538T1 (de) 2005-11-15
DE60023686T2 (de) 2006-07-20
CN1354749A (zh) 2002-06-19
CN1150187C (zh) 2004-05-19
US6303606B1 (en) 2001-10-16
SI1177190T1 (sl) 2006-02-28
HK1039900A1 (en) 2002-05-17
PL351624A1 (en) 2003-05-19
NZ515240A (en) 2003-09-26
HUP0201184A2 (en) 2002-10-28
IL146003A0 (en) 2002-07-25
HK1039900B (en) 2006-02-03
WO2000067735A2 (en) 2000-11-16
WO2000067735A3 (en) 2001-02-01
AU765487B2 (en) 2003-09-18
US20020161009A1 (en) 2002-10-31
NO20015428D0 (no) 2001-11-06
KR100696755B1 (ko) 2007-03-19
DK1177190T3 (da) 2006-02-20
CA2366201A1 (en) 2000-11-16
BR0010348A (pt) 2002-02-13
RU2239633C2 (ru) 2004-11-10
JP2002544158A (ja) 2002-12-24
AU4565400A (en) 2000-11-21
EP1177190B1 (en) 2005-11-02
EP1177190A2 (en) 2002-02-06
US6953800B2 (en) 2005-10-11

Similar Documents

Publication Publication Date Title
NO20015428D0 (no) Anvendelse av selektive antagonister for den &lt;alfa&gt;1b- adrenerge reseptor for forbedring av seksuell dysfunksjon
TNSN01166A1 (fr) Composes agonistes selectifs des recepteurs ep4 et compositions les contenant.
EA200000718A1 (ru) Композиции целекоксиба
SV2002000195A (es) Compuestos farmaceuticamente activos ref. pcs10342 afae/bb
TNSN01100A1 (fr) Derives de glutaramide a substituant cyclopentyle, procede pour leur preparation et compositions les contenant
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
HUP0204159A3 (en) Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
TNSN02011A1 (fr) Derives de pyrimidine bicycliques nouveaux, inhibiteurs de mmp, et compositions les contenant
ATE206119T1 (de) Thiacyclische piperidinylderivate
HUP0301892A2 (hu) Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
EA200200207A1 (ru) Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
BG106602A (en) Formulation of substituted benzimidazoles
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
DE60013486D1 (de) Verbindungen
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
EA200100618A1 (ru) Антагонист витронектинового рецептора
DK1102594T3 (da) Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin
TR199900730T2 (xx) S�v� alendronat form�lasyonlar�
TNSN01112A1 (fr) Agent therapeutique cristallin
RU2003126513A (ru) Состав офлоксацина для инъекций
RU2002111655A (ru) Антигистаминное средство &#34;Бравегил&#34;